Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor

Vincent J. Merluzzi(Boehringer Ingelheim (United States)), Karl D. Hargrave(Boehringer Ingelheim (United States)), Mark E. Labadia(Boehringer Ingelheim (United States)), Karl Grozinger(Boehringer Ingelheim (United States)), Mark T. Skoog(Boehringer Ingelheim (United States)), Joseph C. Wu(Boehringer Ingelheim (United States)), Cheng-Kon Shih(Boehringer Ingelheim (United States)), Kristine Eckner(Boehringer Ingelheim (United States)), Susan E. Hattox(Boehringer Ingelheim (United States)), Julian Adams(Boehringer Ingelheim (United States)), Alan S. Rosenthal(Boehringer Ingelheim (United States)), Ronald B. Faanes(Boehringer Ingelheim (United States)), Robert J. Eckner(Boehringer Ingelheim (United States)), Richard A. Koup(University of Massachusetts Chan Medical School), John L. Sullivan(University of Massachusetts Chan Medical School)
Science
December 7, 1990
Cited by 746

Abstract

A series of dipyridodiazepinones have been shown to be potent inhibitors of human immunodeficiency virus-1 (HIV-1) reverse transcriptase (RT). One compound, BI-RG-587, had a Ki of 200 nanomolar for inhibition of HIV-1 RT that was noncompetitive with respect to deoxyguanosine triphosphate. BI-RG-587 was specific for HIV-1 RT, having no effect on feline and simian RT or any mammalian DNA polymerases. BI-RG-587 inhibited HIV-1 replication in vitro as demonstrated by in situ hybridization, inhibition of protein p24 production, and the lack of syncytia formation in cultured human T cell lines and freshly isolated human peripheral blood lymphocytes. Cytotoxicity studies of BI-RG-587 on human cells showed a high therapeutic index (greater than 8000) in culture.


Related Papers

No related papers found

Powered by citation graph analysis